Tal Harmelech
Research Subjects
Tal Harmelech has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Aron Tendler
GrayMatters Health, Haifa 3303403, Israel
4 shared publications Yiftach Roth
BrainsWay Ltd., 19 Hartum St. Har Hotzvim, Jerusalem, 9777518, Israel; Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben Gurion University of the Negev, Beer Sheva, Israel
2 shared publicationsAbraham Zangen
Department of Life Sciences and the Zlotowski Center for Neuroscience, Ben-Gurion University, Israel
1 shared publication- Abraham Zangen
Faculty of Life Sciences, Ben-Gurion University of the Negev, Be’er Sheva, Israel
1 shared publication Carlene MacMillan
Brooklyn Minds, 347 Grand St, Brooklyn, NY, 11211, USA
1 shared publication- Colleen A. Hanlon
Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, USA
1 shared publication
Latest Publications
- Open Access
- 14 July 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (7) , 1072
Transcranial Magnetic Stimulation as a Tool to Promote Smoking Cessation and Decrease Drug and Alcohol Use
Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive, drug-free, neural-circuit-based therapeutic tool that was recently cleared by the United States Food and Drug Associate for the treatment of smoking cessation. TMS has been investigated as a tool to reduce consumption and craving for many other substance use disorders (SUDs). This review starts with a discussion of neural networks involved in the addiction process. It then provides a framework for the therapeutic efficacy of TMS describing the role of executive control circuits, default mode, and salience circuits as putative targets for neuromodulation (via targeting the DLPFC, MPFC, cingulate, and insula bilaterally). A series of the largest studies of TMS in SUDs are listed and discussed in the context of this framework. Our review concludes with an assessment of the current state of knowledge regarding the use of rTMS as a therapeutic tool in reducing drug, alcohol, and nicotine use and identifies gaps in the literature that need to be addressed in future studies. Namely, while the presumed mechanism through which TMS exerts its effects is by modulating the functional connectivity circuits involved in executive control and salience of drug-related cues, it is also possible that TMS has direct effects on subcortical dopamine, a hypothesis that could be explored in greater detail with PET imaging.
- 14 July 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (7) , 1072
Open AccessTranscranial Magnetic Stimulation as a Tool to Promote Smoking Cessation and Decrease Drug and Alcohol Use
Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive, drug-free, neural-circuit-based therapeutic tool that was recently cleared by the United States Food and Drug Associate for the treatment of smoking cessation. TMS has been investigated as a tool to reduce consumption and craving for many other substance use disorders (SUDs). This review starts with a discussion of neural networks involved in the addiction process. It then provides a framework for the therapeutic efficacy of TMS describing the role of executive control circuits, default mode, and salience circuits as putative targets for neuromodulation (via targeting the DLPFC, MPFC, cingulate, and insula bilaterally). A series of the largest studies of TMS in SUDs are listed and discussed in the context of this framework. Our review concludes with an assessment of the current state of knowledge regarding the use of rTMS as a therapeutic tool in reducing drug, alcohol, and nicotine use and identifies gaps in the literature that need to be addressed in future studies. Namely, while the presumed mechanism through which TMS exerts its effects is by modulating the functional connectivity circuits involved in executive control and salience of drug-related cues, it is also possible that TMS has direct effects on subcortical dopamine, a hypothesis that could be explored in greater detail with PET imaging.
- Open Access
- 15 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (4) , 1015
Efficacy of Deep TMS with the H1 Coil for Anxious Depression
(1) Background: While the therapeutic efficacy of Transcranial Magnetic Stimulation (TMS) for major depressive disorder (MDD) is well established, less is known about the technique’s efficacy for treating comorbid anxiety. (2) Methods: Data were retrospectively analyzed from randomized controlled trials (RCTs) that used Deep TMS with the H1 Coil for MDD treatment. The primary endpoint was the difference relative to sham treatment following 4 weeks of stimulation. The effect size was compared to literature values for superficial TMS and medication treatments. (3) Results: In the pivotal RCT, active Deep TMS compared with sham treatment showed significantly larger improvements in anxiety score (effect size = 0.34, p = 0.03 (FDR)) which were sustained until 16 weeks (effect size = 0.35, p = 0.04). The pooled effect size between all the RCTs was 0.55, which compares favorably to alternative treatments. A direct comparison to Figure-8 Coil treatment indicated that treatment with the H1 Coil was significantly more effective (p = 0.042). In contrast to previously reported studies using superficial TMS and medication for which anxiety has been shown to be a negative predictor of effectiveness, higher baseline anxiety was found to be predictive of successful outcome for the H1-Coil treatment. (4) Conclusions: Deep TMS is effective in treating comorbid anxiety in MDD and, unlike alternative treatments, the outcome does not appear to be adversely affected by high baseline anxiety levels.
- 15 February 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (4) , 1015
Open AccessEfficacy of Deep TMS with the H1 Coil for Anxious Depression
(1) Background: While the therapeutic efficacy of Transcranial Magnetic Stimulation (TMS) for major depressive disorder (MDD) is well established, less is known about the technique’s efficacy for treating comorbid anxiety. (2) Methods: Data were retrospectively analyzed from randomized controlled trials (RCTs) that used Deep TMS with the H1 Coil for MDD treatment. The primary endpoint was the difference relative to sham treatment following 4 weeks of stimulation. The effect size was compared to literature values for superficial TMS and medication treatments. (3) Results: In the pivotal RCT, active Deep TMS compared with sham treatment showed significantly larger improvements in anxiety score (effect size = 0.34, p = 0.03 (FDR)) which were sustained until 16 weeks (effect size = 0.35, p = 0.04). The pooled effect size between all the RCTs was 0.55, which compares favorably to alternative treatments. A direct comparison to Figure-8 Coil treatment indicated that treatment with the H1 Coil was significantly more effective (p = 0.042). In contrast to previously reported studies using superficial TMS and medication for which anxiety has been shown to be a negative predictor of effectiveness, higher baseline anxiety was found to be predictive of successful outcome for the H1-Coil treatment. (4) Conclusions: Deep TMS is effective in treating comorbid anxiety in MDD and, unlike alternative treatments, the outcome does not appear to be adversely affected by high baseline anxiety levels.
- Open Access
- 1 January 2022
- Published by Elsevier in Brain Stimulation
- Vol. 15 (1) , 226-228
Long-term outcomes of a course of deep TMS for treatment-resistant OCD
- 1 January 2022
- Published by Elsevier in Brain Stimulation
- Vol. 15 (1) , 226-228
Open AccessLong-term outcomes of a course of deep TMS for treatment-resistant OCD
- Open Access
- 1 July 2020
- Published by Elsevier in Brain Stimulation
- Vol. 13 (4) , 1000-1001
Do comorbid OCD-MDD patients need two separate dTMS protocols?
- 1 July 2020
- Published by Elsevier in Brain Stimulation
- Vol. 13 (4) , 1000-1001
Open AccessDo comorbid OCD-MDD patients need two separate dTMS protocols?